title: [Antithrombotic therapy in patients with atrial fibrillation: a comment on the European guidelines].
authors.forename: S M
authors.initials: SM
authors.lastname: Said
authors.forename: W
authors.initials: W
authors.lastname: Nahrendorf
authors.forename: H
authors.initials: H
authors.lastname: Schmidt
authors.forename: R C
authors.initials: RC
authors.lastname: Braun-Dullaeus
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy*; D019317:Evidence-Based Medicine; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005858:Germany; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced; D006801:Humans; D019934:International Normalized Ratio; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D020521:Stroke / Q000097:blood / Q000517:prevention & control*; D013923:Thromboembolism / Q000097:blood / Q000517:prevention & control*; D014812:Vitamin K / Q000037:antagonists & inhibitors
chemical_list: D005343:Fibrinolytic Agents; D014812:Vitamin K